Navigation Links
MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
Date:3/16/2011

MARIETTA, Ga., March 16, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it will present at the 10th Annual Needham Healthcare Conference in New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO of MiMedx, and John Daniel, President of Surgical Biologics, a wholly-owned subsidiary of MiMedx, are scheduled to present on Wednesday, April 6th, at 10:00 a.m. Eastern Time at the New York Palace Hotel in New York City.  A webcast of this presentation will be available on the Company's website, www.mimedx.com.  

About the Company

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants manufactured from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability.  Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Announces Launch of AmnioFix™
2. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
3. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
4. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
5. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
6. MiMedx Group Announces Temporary Trading Symbol Designation
7. Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
8. Photonic Products Group, Inc. Announces New Sales and Marketing VP
9. Encorium Group, Inc. Announces New Business Contract Wins of $6.8 Million, Including Two Pivotal Phase III Studies for a Major Asian Technology Company
10. Anpath Group, Inc. Announces Fiscal 2010 Third Quarter Results
11. Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):